AYRWF Ayr Wellness (AYRWF) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Medicinal chemicals & botanical products · CIK 0001847462
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
Ayr Wellness insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for Ayr Wellness Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Canadian issuer: its insiders report trades in Canada on SEDI, not on SEC Form 4, so their buys and sells do not appear here.
Insider
Filed
Shares
Value
Since filing
no insider purchases or sales on record
0 transactions on record
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
+0.0% year over year
below 56% of Pharma & Biotech
Margin
-77.5% net margin
below 55% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
<0.1% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
the lowest in Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch AYRWF
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
Who owns AYRWF: institutional holders (13F)
13F holdings, latest reported quarter
510,991 sh
$7.9K
12,946 sh
$201
Congress trades in AYRWF
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
AYRWF planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
Each figure here is a federal filing, dated the day it went public, so you can test what was knowable then.
AYRWF financials
Revenue growth
0.0%
XBRL, annual
Net margin
-77.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Revenue, TTM AYRWF
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| FY Dec 2020 | n/a |
| none filed |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Net margin, TTM AYRWF
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| FY Dec 2020 | n/a |
| none filed |
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
fewer than four consecutive quarters of operating cash flow
Free cash flow, TTM AYRWF
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| FY Dec 2020 | n/a |
| none filed |
At each fiscal year end
Single quarter
Debt to equity
1.08x
long-term 2024-12-31 plus current 2024-12-31; equity 2024-12-31
Debt to equity AYRWF
| FY Dec 2024 | 1.08x |
| FY Dec 2023 | 0.75x |
| FY Dec 2022 | 0.21x |
| FY Dec 2021 | n/a |
| FY Dec 2020 | n/a |
| none filed |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
needs four quarters of operating cash flow
Cash flow to debt AYRWF
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| FY Dec 2020 | n/a |
| none filed |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
fewer than four consecutive quarters of net income
Return on equity AYRWF
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| FY Dec 2020 | n/a |
| none filed |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
n/a
fewer than four consecutive quarters of net income
Return on assets AYRWF
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| FY Dec 2020 | n/a |
| none filed |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on invested capital AYRWF
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| FY Dec 2020 | n/a |
| none filed |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
Return on capital employed AYRWF
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| FY Dec 2020 | n/a |
| none filed |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
P/E, trailing AYRWF
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| FY Dec 2020 | n/a |
| none filed |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no close on file at or before the as-of date
Enterprise value AYRWF
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| FY Dec 2020 | n/a |
| none filed |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
no close on file at or before the as-of date
FCF yield AYRWF
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| FY Dec 2020 | n/a |
| none filed |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
PEG, trailing AYRWF
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| FY Dec 2020 | n/a |
| none filed |
At each fiscal year end
Trailing four quarters at each quarter end
Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2024-12 | 2023-12 | 2022-12 | 2021-12 | |
|---|---|---|---|---|
| Revenue | $463.6M | $463.6M | $421.4M | n/a |
| Gross profit | $176.7M | $202.4M | $175.0M | $138.1M |
| Operating income | -$161.0M | -$37.1M | -$207.3M | n/a |
| Net income | -$359.3M | -$272.4M | -$245.5M | -$17.0M |
| EPS (diluted) | -3.24 | -3.68 | -3.58 | n/a |
| Operating cash flow | $9.6M | $27.2M | -$34.2M | n/a |
| Cash | n/a | $50.8M | $76.8M | n/a |
| Long-term debt | $385.6M | $411.3M | $136.3M | n/a |
SEC XBRL, fiscal years, as known on 2026-10-28
AYRWF Stock Sonar score 3/7 axes
Find similar shapesCompareAYRWF ranks highest on risk and compliance (99th percentile) and growth (44th), and lowest on financial health (17th), among Pharma & Biotech peers.
3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
